Israel’s drugmaker Teva Pharmaceutical Industries has signed an agreement to acquire 51% equity share in US-based genomic-analysis firm Immuneering.

The deal’s terms have not been disclosed. Based in Cambridge, Massachusetts, US Immuneering provides data analysis services for pharmaceutical companies.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal provides Teva exclusive rights to Immuneering’s cutting-edge analytics that can be used to develop treatments for diseases of the central nervous system (CNS).

"This capability is invaluable in capturing difficult-to-find signals, confirming them in follow-up experiments, and informing decision-making that de-risks and optimises development of therapeutic approaches."

Teva global R&D president and chief scientific officer Michael Hayden said: "Their ability to cut through, link and interpret enormous and disparate data-sets is outstanding.

"This capability is invaluable in capturing difficult-to-find signals, confirming them in follow-up experiments, and informing decision-making that de-risks and optimises development of therapeutic approaches."

See Also:

Immuneering is involved in analysing data sets ranging from gene expression (microarray) data to single-nucleotide polymorphism (SNP) data, as well as protein concentration data to clinical meta data.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also analyses next-generation sequencing (NGS) data, including RNA seq, and both exome and whole genome sequencing.

The company will use these data sets to capture difficult-to-find signals, generate biological hypotheses and design follow-up studies that can be used to develop medicines to treat patients with a wide range of serious diseases.

Immuneering CEO and co-founder Dr Ben Zeskind said: "Immuneering is pioneering new ways to use gene expression and genomic data to elucidate the biological mechanisms underlying both the development of disease, and the effectiveness of medicines."

Last month, Teva signed an agreement with Allergan to acquire its generic drug unit Allergan Generics for around $40.5bn.